CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M

CVRx, Inc.

2024-Q3 EPS reported -$2.25 revenue$35,950,000

US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.
Net loss of $13.1M ($0.57/share) vs $9.0M ($0.43/share) a year ago; SG&A expenses up 38%.
Active implanting centers reached 208, up 31% YoY; cash $100.2M after drawing $20M loan tranche.
CMS reassigned Barostim to MS-DRG 276, raising inpatient payment to ~$43,000 from $17-23K.
FY2024 revenue guidance narrowed to $50.5-51.5M (from $50-53M); operating expense guidance raised to ~$100M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.